Q1 2025 (2.75 / 5 stars) *upgrade
Thanks for the review, Wolf. Despite the trifecta, I'm staying out of this because of the SBC plan & late filings.
Thanks Wolf nice comparison to neupath and yet late filings after oayfare, hash concerning. Keep up the great work.
Thanks for another impartial review. I admit that there is hair on the company. That is why it is trading at such a low level. But, if the company continues to grow revenues and earnings, it could re-rate much higher.
Thanks for the review, Wolf. Despite the trifecta, I'm staying out of this because of the SBC plan & late filings.
Thanks Wolf nice comparison to neupath and yet late filings after oayfare, hash concerning. Keep up the great work.
Thanks for another impartial review. I admit that there is hair on the company. That is why it is trading at such a low level. But, if the company continues to grow revenues and earnings, it could re-rate much higher.